.Pharmacolibrary.Drugs.C_CardiovascularSystem.C10A_LipidModifyingAgentsPlain.C10AA08_Pitavastatin.Pitavastatin

Information

Pitavastatin is a synthetic lipid-lowering agent of the statin class used to treat hypercholesterolemia and mixed dyslipidemia. It selectively inhibits HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis. Pitavastatin is currently approved in many countries for the treatment of elevated cholesterol to reduce cardiovascular risk.

Pharmacokinetics

Pharmacokinetic parameters of pitavastatin following single 2 mg oral dose in healthy adult males.

References

1. Chung, JY, et al., & Jang, IJ (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical pharmacology and therapeutics 78(4) 342–350. DOI:10.1016/j.clpt.2005.07.003 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16198653

2. Huang, YH, et al., & Wang, BH (2014). Comparison of scaled-average, population, and individual bioequivalence on 2 tablets of pitavastatin calcium: a 3-period, reference-replicated, crossover study in healthy Chinese volunteers. Clinical therapeutics 36(9) 1205–1216.e6. DOI:10.1016/j.clinthera.2014.06.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25234550

3. Ahmad, H, & Cheng-Lai, A (2010). Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cardiology in review 18(5) 264–267. DOI:10.1097/CRD.0b013e3181ebdb2f PUBMED:https://pubmed.ncbi.nlm.nih.gov/20699675

Revisions

• 06/2025 initial generated model